{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:45:37Z","timestamp":1784346337684,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"17","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273293"],"award-info":[{"award-number":["82273293"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972468"],"award-info":[{"award-number":["81972468"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2025,5,13]]},"DOI":"10.1038\/s41388-025-03296-1","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T20:03:53Z","timestamp":1738785833000},"page":"1153-1166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The coagulation and tumor system are directly linked through the proteolysis and activation of epidermal growth factor receptor by thrombin"],"prefix":"10.1038","volume":"44","author":[{"given":"Tianfa","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3788-4159","authenticated-orcid":false,"given":"Sanjian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3852-9781","authenticated-orcid":false,"given":"Bing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"3296_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung HYA, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-Cancer J Clin. 2024;74:229\u201363.","journal-title":"Ca-Cancer J Clin"},{"key":"3296_CR2","doi-asserted-by":"publisher","first-page":"1200.","DOI":"10.1038\/s41467-024-45340-w","volume":"15","author":"Y Li","year":"2024","unstructured":"Li Y, Jiang ML, Aye L, Luo L, Zhang Y, Xu FK, et al. UPP1 promotes lung adenocarcinoma progression through the induction of an immunosuppressive microenvironment. Nat Commun. 2024;15:1200.","journal-title":"Nat Commun"},{"key":"3296_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","volume":"389","author":"FR Hirsch","year":"2017","unstructured":"Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ, Wu YL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389:299\u2013311.","journal-title":"Lancet"},{"key":"3296_CR4","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/JCO.2017.72.4401","volume":"35","author":"MG Kris","year":"2017","unstructured":"Kris MG, Gaspar LE, Chaft JE, Kennedy EB, Azzoli CG, Ellis PM, et al. EAdjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology\/Cancer Care Ontario Clinical Practice Guideline Update. J Clin Oncol. 2017;35:2960.","journal-title":"J Clin Oncol"},{"key":"3296_CR5","doi-asserted-by":"publisher","first-page":"e36861.","DOI":"10.1097\/MD.0000000000036861","volume":"103","author":"HY Guo","year":"2024","unstructured":"Guo HY, Zhang J, Qin C, Yan H, Luo XY, Zhou HN. Advances and challenges of first-line immunotherapy for non-small cell lung cancer: A review. Medicine. 2024;103:e36861.","journal-title":"Medicine"},{"key":"3296_CR6","doi-asserted-by":"publisher","first-page":"52.","DOI":"10.1007\/s10238-024-01298-z","volume":"24","author":"ZW Guo","year":"2024","unstructured":"Guo ZW, Wei X, Tang CH, Liang J. Non-tumor-related prognostic factors for immunotherapy-chemotherapy or immunotherapy alone as first-line in advanced non-small cell lung cancer (NSCLC). Clin Exp Med. 2024;24:52.","journal-title":"Clin Exp Med"},{"key":"3296_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1055\/s-0041-1729920","volume":"30","author":"JE Naschitz","year":"2021","unstructured":"Naschitz JE. Cancer-Associated Atherothrombosis: The Challenge. Int J Angiol. 2021;30:249\u201356.","journal-title":"Int J Angiol"},{"key":"3296_CR8","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jtha.2023.02.029","volume":"21","author":"A Falanga","year":"2023","unstructured":"Falanga A, Marchetti M. Cancer-associated thrombosis: enhanced awareness and pathophysiologic complexity. J Thromb Haemost. 2023;21:1397\u2013408.","journal-title":"J Thromb Haemost"},{"key":"3296_CR9","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","volume":"122","author":"JF Timp","year":"2013","unstructured":"Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122:1712\u201323.","journal-title":"Blood"},{"key":"3296_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/jth.12075","volume":"11","author":"A Falanga","year":"2013","unstructured":"Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: biological and clinical aspects. J Thromb Haemost. 2013;11:223\u201333.","journal-title":"J Thromb Haemost"},{"key":"3296_CR11","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3324\/haematol.2015.139816","volume":"101","author":"EA Beleva","year":"2016","unstructured":"Beleva EA, Deneva T, Stoencheva S, Popov V, Grudeva-Popova Z. Hemostatic Biomarkers Based Predictive Model for Metastatic Disease, Progression and Mortality in Cancer Patients. Haematologica. 2016;101:142\u2013142.","journal-title":"Haematologica"},{"key":"3296_CR12","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1016\/j.thromres.2018.01.017","volume":"164","author":"A Falanga","year":"2018","unstructured":"Falanga A, Marchetti M. Hemostatic biomarkers in cancer progression. Thromb Res. 2018;164:S54\u2013S61.","journal-title":"Thromb Res"},{"key":"3296_CR13","doi-asserted-by":"publisher","first-page":"104245.","DOI":"10.1016\/j.critrevonc.2023.104245","volume":"194","author":"D Vanrusselt","year":"2024","unstructured":"Vanrusselt D, Sleurs C, Arif M, Lemiere J, Verschueren S, Uyttebroeck A. Biomarkers of fatigue in oncology: A systematic review. Crit Rev Oncol Hemat. 2024;194:104245.","journal-title":"Crit Rev Oncol Hemat"},{"key":"3296_CR14","doi-asserted-by":"publisher","first-page":"80.","DOI":"10.31083\/j.fbl2902080","volume":"29","author":"HY Hu","year":"2024","unstructured":"Hu HY, Song HQ, Han B, Zhao HL, He JF. Tumor-Educated Platelet RNA and Circulating Free RNA: Emerging Liquid Biopsy Markers for Different Tumor Types. Front Biosci-Landmrk. 2024;29:80.","journal-title":"Front Biosci-Landmrk"},{"key":"3296_CR15","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.ejso.2013.06.008","volume":"39","author":"PP Zhang","year":"2013","unstructured":"Zhang PP, Sun JW, Wang XY, Liu XM, Li K. Preoperative plasma D-dimer levels predict survival in patients with operable non-small cell lung cancer independently of venous thromboembolism. Ejso-Eur J Surg Onc. 2013;39:951\u20136.","journal-title":"Ejso-Eur J Surg Onc"},{"key":"3296_CR16","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s00262-020-02739-w","volume":"70","author":"Z Saidak","year":"2021","unstructured":"Saidak Z, Soudet S, Lottin M, Salle V, Sevestre MA, Clatot F, et al. A pan-cancer analysis of the human tumor coagulome and its link to the tumor immune microenvironment. Cancer Immunol Immun. 2021;70:923\u201333.","journal-title":"Cancer Immunol Immun"},{"key":"3296_CR17","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/S0049-3848(20)30395-9","volume":"191","author":"M Marchetti","year":"2020","unstructured":"Marchetti M, Falanga A. Hemostatic biomarkers in occult cancer and cancer risk prediction. Thromb Res. 2020;191:S37\u2013S42.","journal-title":"Thromb Res"},{"key":"3296_CR18","first-page":"e19189.","volume":"13","author":"J Varkey","year":"2021","unstructured":"Varkey J, Nicolaides T. Tumor-Educated Platelets: A Review of Current and Potential Applications in Solid Tumors. Cureus. J Med Sci. 2021;13:e19189.","journal-title":"J Med Sci"},{"key":"3296_CR19","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1158\/0008-5472.CAN-15-0964","volume":"75","author":"GN Adams","year":"2015","unstructured":"Adams GN, Rosenfeldt L, Frederick M, Miller W, Waltz D, Kombrinck K, et al. Colon Cancer Growth and Dissemination Relies upon Thrombin, Stromal PAR-1, and Fibrinogen. Cancer Res. 2015;75:4235\u201343.","journal-title":"Cancer Res"},{"key":"3296_CR20","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/cas.15653","volume":"114","author":"M Shimoda","year":"2023","unstructured":"Shimoda M. Modulation of tissue microenvironmental factors in tumor progression. Cancer Sci. 2023;114:921\u2013921.","journal-title":"Cancer Sci"},{"key":"3296_CR21","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1055\/s-0039-1687895","volume":"45","author":"AMR Rondon","year":"2019","unstructured":"Rondon AMR, Kroone C, Kapteijn MY, Versteeg HH, Buijs JT. Role of Tissue Factor in Tumor Progression and Cancer-Associated Thrombosis. Semin Thromb Hemost. 2019;45:396\u2013412.","journal-title":"Semin Thromb Hemost"},{"key":"3296_CR22","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/jso.21668","volume":"102","author":"LA Tang","year":"2010","unstructured":"Tang LA, Liu K, Wang JF, Wang C, Zhao P, Liu JZ. High Preoperative Plasma Fibrinogen Levels Are Associated With Distant Metastases and Impaired Prognosis After Curative Resection in Patients With Colorectal Cancer. J Surg Oncol. 2010;102:428\u201332.","journal-title":"J Surg Oncol"},{"key":"3296_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1160\/TH16-05-0416","volume":"117","author":"B Zhao","year":"2017","unstructured":"Zhao B, Zhang YL, Huang YN, Yu JC, Li YR, Wang Q, et al. A novel hirudin derivative inhibiting thrombin without bleeding for subcutaneous injection. Thromb Haemostasis. 2017;117:44\u201356.","journal-title":"Thromb Haemostasis"},{"key":"3296_CR24","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1182\/blood-2005-04-1710","volume":"106","author":"DA Lane","year":"2005","unstructured":"Lane DA, Philippou H, Huntington JA. Directing thrombin. Blood. 2005;106:2605\u201312.","journal-title":"Blood"},{"key":"3296_CR25","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1002\/hep.23942","volume":"52","author":"YH Xue","year":"2010","unstructured":"Xue YH, Zhang XF, Dong QZ, Sun JA, Dai C, Zhou HJ, et al. Thrombin is a Therapeutic Target for Metastatic Osteopontin-Positive Hepatocellular Carcinoma. Hepatology. 2010;52:2012\u201322.","journal-title":"Hepatology"},{"key":"3296_CR26","first-page":"1556","volume":"5","author":"B Zhao","year":"2020","unstructured":"Zhao B, Wu MF, Hu ZH, Ma YX, Qi W, Zhang YL, et al. Thrombin is a therapeutic target for non-small-cell lung cancer to inhibit vasculogenic mimicry formation. Signal Transduct Tar. 2020;5:1556\u201367.","journal-title":"Signal Transduct Tar"},{"key":"3296_CR27","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/jth.13612","volume":"15","author":"CJ Reddel","year":"2017","unstructured":"Reddel CJ, Allen JD, Ehteda A, Taylor R, Chen VMY, Curnow JL, et al. Increased thrombin generation in a mouse model of cancer cachexia is partially interleukin-6 dependent. J Thromb Haemost. 2017;15:477\u201386.","journal-title":"J Thromb Haemost"},{"key":"3296_CR28","doi-asserted-by":"publisher","first-page":"3480.","DOI":"10.3390\/cancers15133480","volume":"15","author":"LL Leung","year":"2023","unstructured":"Leung LL, Myles T, Morser J. Thrombin Cleavage of Osteopontin and the Host Anti-Tumor Immune Response. Cancers. 2023;15:3480.","journal-title":"Cancers"},{"key":"3296_CR29","doi-asserted-by":"publisher","first-page":"3847.","DOI":"10.1038\/s41467-018-06299-7","volume":"9","author":"M Baumdick","year":"2018","unstructured":"Baumdick M, Gell\u00e9ri M, Uttamapinant C, Ber\u00e1nek V, Chin JW, Bastiaens PIH. A conformational sensor based on genetic code expansion reveals an autocatalytic component in EGFR activation. Nat Commun. 2018;9:3847.","journal-title":"Nat Commun"},{"key":"3296_CR30","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.molcel.2018.03.018","volume":"70","author":"JH Lee","year":"2018","unstructured":"Lee JH, Liu R, Li J, Wang YG, Tan L, Li XJ, et al. EGFR-Phosphorylated Platelet Isoform of Phosphofructokinase 1 Promotes PI3K Activation. Mol Cell. 2018;70:197.","journal-title":"Mol Cell"},{"key":"3296_CR31","doi-asserted-by":"publisher","first-page":"27160","DOI":"10.1074\/jbc.M116.763235","volume":"291","author":"NC Law","year":"2016","unstructured":"Law NC, White MF, Hunzicker-Dunn ME. G protein-coupled receptors (GPCRs) That Signal via Protein Kinase A (PKA) Cross-talk at Insulin Receptor Substrate 1 (IRS1) to Activate the phosphatidylinositol 3-kinase (PI3K)\/AKT Pathway. J Biol Chem. 2016;291:27160\u20139.","journal-title":"J Biol Chem"},{"key":"3296_CR32","doi-asserted-by":"publisher","first-page":"425.","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Tar. 2021;6:425.","journal-title":"Signal Transduct Tar"},{"key":"3296_CR33","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.apsb.2018.05.010","volume":"8","author":"H Lyu","year":"2018","unstructured":"Lyu H, Han A, Polsdofer E, Liu S, Liu BL. Understanding the biology of HER3 receptor as a therapeutic target in human cancer. Acta Pharm Sin B. 2018;8:503\u201310.","journal-title":"Acta Pharm Sin B"},{"key":"3296_CR34","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jtho.2023.09.1451","volume":"19","author":"J Remon","year":"2024","unstructured":"Remon J, Saw SPL, Cortiula F, Singh PK, Menis J, Mountzios G, et al. Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges. J Thorac Oncol. 2024;19:199\u2013215.","journal-title":"J Thorac Oncol"},{"key":"3296_CR35","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.1158\/0008-5472.CAN-06-4495","volume":"67","author":"P Tooker","year":"2007","unstructured":"Tooker P, Yen WC, Ng SC, Negro-Vilar A, Hermann TW. Bexarotene (LGD1069, targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification. Cancer Res. 2007;67:4425\u201333.","journal-title":"Cancer Res"},{"key":"3296_CR36","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1182\/blood.2023020535","volume":"142","author":"R Kaiser","year":"2023","unstructured":"Kaiser R, Escaig R, Nicolai L. Hemostasis without clot formation: how platelets guard the vasculature in inflammation, infection, and malignancy. Blood. 2023;142:1413\u201325.","journal-title":"Blood"},{"key":"3296_CR37","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1111\/jth.15773","volume":"20","author":"C Comerford","year":"2022","unstructured":"Comerford C, Glavey S, Quinn J, O\u2019Sullivan JM. The role of VWF\/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies. J Thromb Haemost. 2022;20:1766\u201377.","journal-title":"J Thromb Haemost"},{"key":"3296_CR38","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jama.293.6.715","volume":"293","author":"JW Blom","year":"2005","unstructured":"Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. Jama-J Am Med Assoc. 2005;293:715\u201322.","journal-title":"Jama-J Am Med Assoc"},{"key":"3296_CR39","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1182\/blood-2009-10-247296","volume":"115","author":"L Erpenbeck","year":"2010","unstructured":"Erpenbeck L, Sch\u00f6n MP. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood. 2010;115:3427\u201336.","journal-title":"Blood"},{"key":"3296_CR40","first-page":"3267","volume":"52","author":"MLR Nierodzik","year":"1992","unstructured":"Nierodzik MLR, Kajumo F, Karpatkin S. Effect of Thrombin Treatment of Tumor-Cells on Adhesion of Tumor-Cells to Platelets Invitro and Tumor-Metastasis Invivo. Cancer Research. 1992;52:3267\u201372.","journal-title":"Cancer Research"},{"key":"3296_CR41","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1002\/ijc.2910530620","volume":"53","author":"A Klepfish","year":"1993","unstructured":"Klepfish A, Greco MA, Karpatkin S. Thrombin stimulates melanoma tumor-cell binding to endothelial cells and subendothelial matrix. Int J Cancer. 1993;53:978\u201382.","journal-title":"Int J Cancer"},{"key":"3296_CR42","doi-asserted-by":"publisher","first-page":"36.","DOI":"10.1186\/scrt424","volume":"5","author":"J Chen","year":"2014","unstructured":"Chen J, Ma YJ, Wang Z, Wang HX, Wang LS, Xiao FJ, et al. Thrombin promotes fibronectin secretion by bone marrow mesenchymal stem cells via the protease-activated receptor mediated signalling pathways. Stem Cell Res Ther. 2014;5:36.","journal-title":"Stem Cell Res Ther"},{"key":"3296_CR43","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1182\/blood.V92.10.3694","volume":"92","author":"ML Nierodzik","year":"1998","unstructured":"Nierodzik ML, Chen K, Takeshita K, Li JJ, Huang YQ, Feng XS, et al. Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood. 1998;92:3694\u20133700.","journal-title":"Blood"},{"key":"3296_CR44","first-page":"48","volume":"29","author":"DL Ornstein","year":"1999","unstructured":"Ornstein DL, Zacharski LR. The use of heparin for treating human malignancies. Haemostasis. 1999;29:48\u201360.","journal-title":"Haemostasis"},{"key":"3296_CR45","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1111\/j.1538-7836.2004.00871.x","volume":"2","author":"M Altinbas","year":"2004","unstructured":"Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004;2:1266\u201371.","journal-title":"J Thromb Haemost"},{"key":"3296_CR46","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.semcancer.2022.04.002","volume":"85","author":"E Levantini","year":"2022","unstructured":"Levantini E, Maroni G, Del Re M, Tenen DG. EGFR signaling pathway as therapeutic target in human cancers. Semin Cancer Biol. 2022;85:253\u201375.","journal-title":"Semin Cancer Biol"},{"key":"3296_CR47","doi-asserted-by":"publisher","first-page":"1268.","DOI":"10.3390\/jcm9051268","volume":"9","author":"M Zaborowska-Szmit","year":"2020","unstructured":"Zaborowska-Szmit M, Krzakowski M, Kowalski DM, Szmit S. Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer. J Clin Med. 2020;9:1268.","journal-title":"J Clin Med"},{"key":"3296_CR48","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/jso.20728","volume":"95","author":"F Icli","year":"2007","unstructured":"Icli F, Akbulut H, Utkan G, Yalcin B, Dincol D, Isikdogan A, et al. Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J Surg Oncol. 2007;95:507\u201312.","journal-title":"J Surg Oncol"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03296-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03296-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03296-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T09:03:26Z","timestamp":1745312606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03296-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":48,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2025,5,13]]}},"alternative-id":["3296"],"URL":"https:\/\/doi.org\/10.1038\/s41388-025-03296-1","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]},"assertion":[{"value":"23 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The animal experiments were conducted in strict accordance with the guidelines of the Institutional Animal Care and Use Committee (IACUC) of Fudan University Shanghai Cancer Center. Approval for these experiments was obtained under the following permission numbers: FUSCC-IACUC-20190221-128 (Shanghai, China). All experiments using human tissues were performed in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Fudan University, Approval for these experiments was obtained under the following permission numbers: FUSCC-IACUC-2019-C021 (Shanghai, China). Informed consent was obtained from all participants. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}